I couldn't agree more. Johnson and Johnson made over $150,000,000 in 2019 off Neosporin. This product is better and has more uses. I can see them or another big pharma snapping them up. This is a great company on the verge of big things. The market cap is about $23,000,000 which is laughable. We have FDA approval, revenue, patents, licensing, debt free, and a good share structure. We should be trading 10X what we are now. We're light years ahead of most OTC stocks. Very undervalued. I'm loading all I can as funds become available. This will run big on news!
News 
Market Data 
Discover 
